Incorporating Healthy Living Strategies to Aid in Recovery After Acute Pulmonary Embolism
Launched by UNIVERSITY OF ROCHESTER · Jan 14, 2025
Trial Information
Current as of August 21, 2025
Recruiting
Keywords
ClinConnect Summary
The ERAsE-PE study is looking into whether two healthy living strategies can help people recover better after being treated for a pulmonary embolism, which is a blockage in the lungs' blood vessels. Participants in this study will follow an 8-week program while also taking prescribed blood thinners (anticoagulants). Researchers will measure the changes in how hard the heart has to work during a simple 6-minute walking test to see if these strategies make a difference in recovery.
To be eligible for this study, you need to be at least 18 years old, speak English, and have recently been diagnosed with an acute pulmonary embolism that meets specific criteria, such as showing signs of heart strain on tests. Participants should be able to walk and follow daily instructions sent via text or email. If you join the study, you can expect to be part of a supportive program aimed at improving your health and recovery after your hospital stay.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. English speaking (\>18 years old). Daily messages will be sent in English.
- 2. Acute PE with at least one of the following:
- • 1. any right ventricular enlargement or dysfunction on echocardiogram;
- • 2. CT Angiogram reporting any right ventricular enlargement; or
- • 3. elevated cardiac biomarker (NT-pro BNP or troponin above baseline). Criteria for enrollment will be included on source document.
- • 3. Rate controlled atrial arrythmias (resting heart rate \<110 beats/m) are eligible for enrollment. This includes atrial fibrillations. This is standard of care management for atrial fibrillation.
- • 4. Subjects do need to take prescribed anticoagulation.
- Exclusion Criteria:
- • 1. Pregnancy.
- • 2. Cardiac Effort \>3.5 beats/m during 6MWT.
- • 3. Resting tachycardia \>110 beats/m at hospital discharge.
- • 4. Chronic Thromboembolic Pulmonary Hypertension
- • 5. Systolic blood pressure \>180 mmHg at hospital discharge.
- • 6. Inability to walk.
- • 7. Estimated prognosis \<12 months at the time of discharge due to underlying co-morbidities (e.g., cancer).
- • 8. Advanced neurologic disease and would not be able to comply with the messages.
- • 9. Lack of access to email or text messaging 10. Inability or unwillingness to follow daily instructions.
About University Of Rochester
The University of Rochester is a leading academic institution dedicated to advancing medical research and improving patient care through innovative clinical trials. Renowned for its commitment to excellence in education, research, and clinical practice, the university fosters a collaborative environment that integrates cutting-edge scientific inquiry with practical applications in healthcare. With a focus on diverse therapeutic areas, the University of Rochester aims to enhance treatment options and outcomes for patients while contributing to the broader scientific community through rigorous study design and ethical standards in clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Rochester, New York, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported